Grade Post Therapy Clin (yc) (Cervix Sarcoma)
Organization | Field Name | ID# | ID Name | Required |
---|---|---|---|---|
KCR | Grade Post Therapy Clin (yc) | 30141 | GradePostTherapyClin | yes |
SEER | Grade Post Therapy Clin (yc) | gradePostTherapyClin | yes |
Note 1 Leave post therapy grade blank when
No neoadjuvant therapy
Clinical or pathological case only
Neoadjuvant therapy completed, no microscopic exam is done prior to surgery/resection of primary tumor
There is only one grade available and it cannot be determined if it is clinical, pathological, post therapy clinical or post therapy pathological
Note 2 Assign the highest grade from the microscopically sampled specimen of the primary site following neoadjuvant therapy or primary systemic/radiation therapy.
Per clarification from the CAP Cancer Committee based on the CAP Protocol, the following histologies must be assigned a G3 (code 3) Serous, clear cell, undifferentiated/de-differentiated carcinomas, carcinosarcomas, and mixed mesodermal tumors (Mullerian/MMMT) are high risk (high grade)
Note 3 For endometrioid carcinomas only
If “low grade” is documented, code 2 (FIGO Grade 2)
If “high grade” is documented, code 3 (FIGO Grade 3)Note 3 If there are multiple tumors with different grades abstracted as one primary, code the highest grade.
Note 4 If there are multiple tumors with different grades abstracted as one primary, code the highest grade.
Note 5 G3 includes anaplastic.
Note 6 Code 9 (unknown) when
Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented
Microscopic exam is done after neoadjuvant therapy and there is no residual cancer
Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available
Code | Description |
---|---|
1 | G1 |
2 | G2 |
3 | G3 |
9 | Grade cannot be assessed (GX); Unknown |
<BLANK> | See Note 1 |